At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 132 enrolled
Drug / intervention
LY2157299 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study of LY2157299 Versus LY2157299 - Sorafenib Combination Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma
In Brief
A Phase 2 clinical trial evaluating LY2157299, Sorafenib, and 1 other intervention for Hepatocellular Carcinoma. Completed, enrolled 132 participants across 16 sites in 5 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesChina, Hong Kong, South Korea, Taiwan, Thailand
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartAug 2014
Primary CompletionJun 2017
Study CompletionFeb 2021
TodayJul 2026
First PostedJun 30, 2014
Enrollment StartAug 8, 2014
Primary CompletionJun 30, 2017
Study CompletionFeb 18, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.0 years ago
Interventions
LY2157299drug
Administered orally
Sorafenibdrug
Administered orally
Placebodrug
Administered orally